The U.S. Food and Drug Administration (FDA) has proposed excluding the active ingredients in widely prescribed obesity and diabetes medications from a list of substances permitted for compounding by large-scale facilities.
The agency determined there is no “clinical need” to allow 503B compounding facilities—large-scale outsourcing operations—to produce large quantities of medicines containing semaglutide or tirzepatide. These ingredients are central to several blockbuster drugs:
- Semaglutide: The active ingredient in Novo Nordisk’s Wegovy (weight-loss) and Ozempic (diabetes).
- Tirzepatide: The active ingredient in Eli Lilly’s Mounjaro (diabetes) and Zepbound (obesity).
The FDA’s decision specifically targets 503B compounders, which have faced scrutiny in recent years for their role in producing compounded weight-loss treatments. In its announcement, the agency stated that these facilities no longer meet the legal requirements to market their compounded products.
The proposal represents a significant shift in the regulatory landscape, aligning with the interests of Novo Nordisk and Eli Lilly while potentially limiting consumer access to alternative versions of these medications.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
GLP-1 Drugs Linked to Better Breast Cancer Outcomes in Obesity and Diabetes Patients
A recent study shows that GLP-1 drugs may help improve survival rates in people with breast cancer, obesity, and diabetes. Image Credit: Tatsiana Volk...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...